Investigational drug · Phase 2
JTM201
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glabellar Lines.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "JTM201"
First trial start
2024
Oct 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JTM201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glabellar Lines
Largest trials
Live from ClinicalTrials.gov: studies naming "JTM201" as an intervention, largest first.
- Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar LinesPivotal-lookingCompleted
Jetema USA Inc.Industry
NCT06246552 · 480 participants · Start Oct 26, 2024 · Primary completion Jun 5, 2025
Drug: JTM201; Placebo · For: Glabellar Lines
Sites: Manhattan Beach, California
Jetema Co., Ltd.Industry
NCT07292025 · 30 participants · Start Jun 29, 2023 · Primary completion Apr 22, 2024
Drug: JTM201 in normal saline; BOTOX 100U in normal saline · For: Upper Limb Spasticity Post-Stroke
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Long-term efficacy and safety of a new botulinum toxin type A preparation in mouse gastrocnemius muscle.
Na J, Lee E, Kim YJ, et al. · Toxicon 2020
Also in development for Glabellar Lines
- AGN-151586Phase 32 trials
AbbVie · Forehead Lines, Glabellar Lines
- HU-045Phase 31 trial
Huons Biopharma · Glabellar Lines
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.